Login to Your Account

'Interesting year for IPOs'

For the first time since BioWorld began tracking the biotech industry's public financings in 1999, five U.S. companies priced their IPOs within a 24-hour period and made their U.S. market debuts on a single day. 

more »

Our Habitat for All Things Science
Ibrutinib could be repurposed to treat glioblastoma

HONG KONG – Preclinical data from a Sino-US study suggest that a tyrosine kinase inhibitor originally developed to treat lymphoma and leukemia, Imbruvica (ibrutinib, Abbvie Inc./Johnson & Johnson), could also target glioma stem cells (GSCs), effectively controlling glioblastoma growth.

Despite therapeutic advances in other solid tumors, glioblastoma remains the most lethal primary brain tumor. It is highly resistant to current treatments including radiotherapy and chemotherapy. The cancer usually recurs rapidly, with a median survival of less than 15 months from diagnosis.



Partners in Focus